Agonist lead identification for the high affinity niacin receptor GPR109a
摘要:
A strategy for lead identification of new agonists of GPR109a, starting from known compounds shown to activate the receptor, is described. Early compound triage led to the formulation of a binding hypothesis and eventually to our focus on a series of pyrazole acid derivatives. Further elaboration of these compounds provided a series of 5,5-fused pyrazoles to be used as lead compounds for further optimization. (C) 2007 Elsevier Ltd. All rights reserved.
Novel heterocyclic compounds having anti-HBV activity
申请人:Chen Huanming
公开号:US20060189643A1
公开(公告)日:2006-08-24
This application relates to novel fused tricyclic thienopyridines of Formulas I and II, which useful for treating Hepatitis B infection and other diseases. This application also relates to pharmaceutical compositions comprising thienopyridines and to the use of such compositions to treat Hepatitis B and other diseases.
NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY
申请人:Chen Huanming
公开号:US20090029983A1
公开(公告)日:2009-01-29
This application relates to novel fused tricyclic thienopyridines of Formulas I and II, which useful for treating Hepatitis B infection and other diseases.
This application also relates to pharmaceutical compositions comprising thienopyridines and to the use of such compositions to treat Hepatitis B and other diseases.